Moreover, although there were no significant differences between the expression of DDIT4 and survival in either PDAC or PNET patients, the pancreatic cancer patients with the high nuclear expression of DDIT4 had shorter survival duration compared to those with the low nuclear expression of DDIT4, which was consistent with our clinicopathological findings. This evidence concerns the gene DDIT4 and primitive neuroectodermal tumor.